Craig Hallum reissued their buy rating on shares of CareDx (NASDAQ:CDNA) in a report released on Friday morning, The Fly reports. The brokerage currently has a $40.00 price objective on the stock.
Several other equities research analysts have also recently weighed in on CDNA. HC Wainwright set a $17.00 price target on CareDx and gave the company a hold rating in a research report on Friday, August 10th. BidaskClub upgraded CareDx from a buy rating to a strong-buy rating in a research report on Tuesday, August 14th. Zacks Investment Research cut CareDx from a buy rating to a sell rating in a research report on Wednesday, August 15th. Piper Jaffray Companies upped their price target on CareDx to $42.00 in a research report on Wednesday, September 5th. Finally, Raymond James reiterated a strong-buy rating and set a $30.00 price target on shares of CareDx in a research report on Tuesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $29.60.
NASDAQ CDNA traded down $2.13 during trading on Friday, hitting $25.61. 2,159,992 shares of the company’s stock traded hands, compared to its average volume of 643,702. The company has a market cap of $1.03 billion, a PE ratio of -33.26 and a beta of 1.06. CareDx has a 12-month low of $4.92 and a 12-month high of $30.15. The company has a quick ratio of 1.83, a current ratio of 2.16 and a debt-to-equity ratio of 0.46.
In related news, major shareholder Neil Gagnon sold 108,599 shares of the company’s stock in a transaction that occurred on Wednesday, October 31st. The shares were sold at an average price of $27.05, for a total value of $2,937,602.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sasha King sold 11,500 shares of the company’s stock in a transaction that occurred on Friday, October 5th. The stock was sold at an average price of $24.60, for a total transaction of $282,900.00. Following the completion of the transaction, the insider now owns 53,542 shares in the company, valued at $1,317,133.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,954 shares of company stock worth $4,187,359. 3.40% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Strs Ohio bought a new position in shares of CareDx in the second quarter worth approximately $116,000. Meeder Asset Management Inc. bought a new position in shares of CareDx in the third quarter worth approximately $124,000. Metropolitan Life Insurance Co. NY bought a new position in shares of CareDx in the second quarter worth approximately $139,000. Voya Investment Management LLC bought a new position in shares of CareDx in the second quarter worth approximately $153,000. Finally, Fox Run Management L.L.C. bought a new position in shares of CareDx in the second quarter worth approximately $178,000. Institutional investors own 74.63% of the company’s stock.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.